Popular Stories
Avise Analytics | Biotechnology
1218
archive,category,category-biotechnology,category-1218,ajax_fade,page_not_loaded,,side_area_uncovered_from_content,qode-child-theme-ver-1.0.0,qode-theme-ver-7.4,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

Biotechnology

Can Cara Therapeutics buck the trend?

Cara Therapeutics (NASDAQ: CARA) recently posted its first quarter, 2019 results. The company reported a net loss of $22.0 million, or $0.56 per basic and diluted share compared to a net loss of $16.8 million, or $0.51 per basic and diluted share, for the first...

G1 Therapeutics stock soars on news of NDA for Triaciclib

G1 Therapeutics (NASDAQ: GTHX) shares soared by almost 25% on the basis of news that it had a productive phase 2 meeting with the FDA for the company’s lead candidate Trilaciclib, a first-in-class myelopreservation agent that protects the bone marrow from damage by chemotherapy. The...

WordPress Video Lightbox Plugin